Current Health Roundup: Walgreens Fraud Settlement, Eli Lilly's Eczema Drug, and More

A summary of current health news including Walgreens settling fraud charges, FDA approval for Eli Lilly's eczema drug, links between mammography findings and heart disease, Uganda's rising mpox infections, and Pfizer's efforts to increase BRAF lung cancer mutation testing.

In today's health news, Walgreens Boots Alliance has agreed to a $106.8 million settlement with the U.S. Department of Justice for fraudulently billing the government for undispensed prescriptions. The settlement addresses violations of the federal False Claims Act from 2009 to 2020.

The FDA has approved Eli Lilly's injectable eczema drug, Ebglyss, for individuals aged 12 and older. The drug is expected to be available in the coming weeks.

Mammography findings that show clogged arteries could indicate heart disease, sparking renewed interest in cardiovascular health research. Another study highlights the potential for video visits to enhance end-of-life care quality.

Uganda has confirmed ten mpox cases, all linked to the clade 1b strain, which is highly transmissible between people. The country is under close watch due to its proximity to the Democratic Republic of Congo, where the outbreak began.

Pfizer is pushing for increased testing for the rare BRAF V600E lung cancer mutation, hoping to establish its drug, Braftovi, as a standard treatment. Three-year data reveals promising survival rates for patients treated with Braftovi and Mektovi.

(With inputs from agencies.)